Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS2598-TPS2598
Keyword(s):
Phase Ii
◽